BVSBioventus Inc.
Price
+91%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Bioventus Inc. (BVS) reported revenue of $153M in Q2 2026 (quarter ended Jun 27, 2026), up 3.8% from the same quarter a year earlier. That came with a gross margin of 69% and net income of $33M (22% of revenue). For the full year FY2025, revenue was $568M (−0.9% year on year) and net income $23M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026As previously announced, following receipt of a recent unsolicited acquisition proposal from a party interested in acquiring the Company and multiple other expressions of interest, the Company’s Board of Directors (the “Board”) established a committee of independent directors, which, with the assistance of independent …Earnings release · Form 8-K
- May 6, 2026Bioventus Reports First Quarter Financial Results.Earnings release · press release
- Mar 5, 2026Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
Ranks #18 of 51 by RyuScore